A Phase 3 interventional study of Inclisiran and Placebo in Familial Hypercholesterolemia - Homozygous, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in 8 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Homozygous Familial Hypercholesterolemia with a site in Greece — 2 open to participants now, 3 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · Greece.
Among the 10 studies in Homozygous Familial Hypercholesterolemia with a site in Greece, this one is the only one that started in 2021, is one of 7 in phase 3, and was the 7th registered.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
Browse Homozygous Familial Hypercholesterolemia studies →2 of the 10 studies in Homozygous Familial Hypercholesterolemia with a site in Greece are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Greece, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Greece, United States, Argentina and 23 more countries
Ages 2–100
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 8
First in 2012; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Median enrollment 93 across the 8 interventional studies, 167 across the 2 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Homozygous Familial Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Homozygous Familial Hypercholesterolemia with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C).
This was a two-part (double-blind, inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) multicenter study in adolescents (aged 12 to \< 18 years) with HoFH and elevated LDL-C (> 130 mg/dL; 3.4 mmol/L) on stable, individualized, optimal standard of care (SoC) background lipid-lowering therapy (including maximally tolerated statin treatment, at the Investigator's discretion) to evaluate the safety, tolerability, and efficacy of inclisiran in this pediatric patient population.
Following an approximately 4-week screening/run-in period, the study had 2 sequential parts as follows:
Part 1/Year 1: 12 months double-blind, parallel group period, in which participants were randomized in a 2:1 ratio to receive either inclisiran sodium 300 mg subcutaneous (s.c.) or placebo. The primary endpoint was assessed at Day 330.
Part 2/Year 2: 12 months single arm, open-label follow-up period, with all participants receiving inclisiran sodium 300 mg s.c.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran sodium 300 mg subcutaneous (sc) injection (given at Days 1, 90 and 270)
Drug: Inclisiran
Placebo sc injection (given at Day 1, 90 and 270)
Drug: Placebo
Inclisiran sodium 300 mg sc injection (given at Days 450 and 630). In addition, participants assigned to placebo in Part 1 received inclisiran sodium 300 mg sc injection on Day 360, while participants assigned to inclisiran in Part 1 received placebo sc injection on Day 360.
Drug: Inclisiran
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
Also known as: KJX839
Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
Also known as: Saline solution
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)
Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)
Time frame: Baseline and Day 330
Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)
Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330
Time frame: Baseline, after Day 90 up to Day 330
Percent Change in LDL-C From Baseline up to Day 720
Percentage change in LDL-C from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in LDL-C From Baseline up to Day 720
Absolute change in LDL-C from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Apo B From Baseline up to Day 720
Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Apo B From Baseline up to Day 720
Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Lp(a) From Baseline up to Day 720
Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Lp(a) From Baseline up to Day 720
Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Non-HDL-C From Baseline up to Day 720
Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Non-HDL-C From Baseline up to Day 720
Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Total Cholesterol From Baseline up to Day 720
Percentage change in total cholesterol from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Total Cholesterol From Baseline up to Day 720
Absolute change in total cholesterol from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Triglycerides From Baseline up to Day 720
Percentage change in triglycerides from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Triglycerides From Baseline up to Day 720
Absolute change in triglycerides from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in HDL-C From Baseline up to Day 720
Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in HDL-C From Baseline up to Day 720
Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in VLDL-C From Baseline up to Day 720
Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolut Change in VLDL-C From Baseline up to Day 720
Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Apo A1 From Baseline up to Day 720
Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Apo A1 From Baseline up to Day 720
Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in PCSK9 From Baseline up to Day 720
Percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolut Change in PCSK9 From Baseline up to Day 720
Absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Thirteen participants were randomized from 9 study centers in 8 countries. The breakdown of countries and study centers for the randomized participants was as follows: Canada (1), France (1), Greece (1), Lebanon (1), Malaysia (1), Netherlands (1), Turkey (2), and United States (1).
| Milestone | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Started | 9 | 4 | 0 |
| Completed | 9 | 4 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Started | 0 | 0 | 13 |
| Completed | 0 | 0 | 13 |
| Not completed | 0 | 0 | 0 |
Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)
| percent change in LDL-C | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) | -21.6 ± 13.36 | 11.7 ± 30.52 |
Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330
| Time-adjusted percent change in LDL-C | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1) | -21.0 ± 15.11 | 13.0 ± 41.88 |
Percentage change in LDL-C from baseline to each assessment time up to Day 720.
| Percent change in LDL-C | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 90 | -26.1 ± 13.53 | 6.8 ± 16.83 | — |
| Day 150 | -24.1 ± 14.65 | 17.0 ± 41.22 | — |
| Day 270 | -17.3 ± 21.64 | 10.2 ± 54.00 | — |
| Day 330 | -21.6 ± 13.36 | 11.7 ± 30.52 | — |
| Day 360 | -19.3 ± 14.75 | 5.4 ± 28.24 | — |
| Day 450 | — | — | -11.0 ± 25.28 |
| Day 510 | — | — | -12.5 ± 22.52 |
| Day 630 | — | — | -9.4 ± 26.16 |
| Day 720 | — | — | -12.6 ± 28.45 |
Absolute change in LDL-C from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 90 | -70.6 ± 48.81 | 16.5 ± 44.96 | — |
| Day 150 | -66.1 ± 61.85 | 20.3 ± 91.34 | — |
| Day 270 | -47.1 ± 83.15 | -9.3 ± 134.14 | — |
| Day 330 | -62.9 ± 52.35 | 11.8 ± 69.94 | — |
| Day 360 | -50.8 ± 44.65 | -4.3 ± 69.84 | — |
| Day 450 | — | — | -36.6 ± 75.08 |
| Day 510 | — | — | -46.8 ± 73.04 |
| Day 630 | — | — | -41.9 ± 92.47 |
| Day 720 | — | — | -39.8 ± 96.59 |
Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
| Percent change in Apo B | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -20.3 ± 12.92 | 10.0 ± 27.05 | — |
| Day 330 | -18.5 ± 10.47 | 4.5 ± 17.91 | — |
| Day 360 | -14.8 ± 10.11 | 10.6 ± 21.33 | — |
| Day 510 | — | — | -5.7 ± 25.96 |
| Day 720 (study completion) | — | — | -7.3 ± 29.36 |
Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -37.3 ± 33.35 | 7.5 ± 48.72 | — |
| Day 330 | -35.8 ± 30.33 | 0.3 ± 35.85 | — |
| Day 360 | -28.7 ± 27.16 | 12.0 ± 32.89 | — |
| Day 510 | — | — | -18.8 ± 45.81 |
| Day 720 (study completion) | — | — | -19.6 ± 51.64 |
Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
| Percent change in Lp(a) | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -0.7 ± 24.81 | -4.4 ± 9.20 | — |
| Day 330 | -0.3 ± 21.27 | -16.5 ± 27.29 | — |
| Day 360 | -1.7 ± 16.57 | -12.1 ± 31.51 | — |
| Day 510 | — | — | -7.2 ± 31.39 |
| Day 720 (study completion) | — | — | -8.8 ± 22.03 |
Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
| nmol/L | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | 8.9 ± 28.41 | -0.3 ± 1.26 | — |
| Day 330 | 2.8 ± 15.01 | 5.3 ± 15.86 | — |
| Day 360 | 5.8 ± 7.03 | 0.5 ± 9.75 | — |
| Day 510 | — | — | 3.0 ± 14.45 |
| Day 720 (study completion) | — | — | -0.3 ± 9.12 |
Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
| Percent change in non-HDL-C | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -24.0 ± 13.83 | 19.0 ± 43.34 | — |
| Day 330 | -23.3 ± 10.99 | 9.4 ± 34.93 | — |
| Day 360 | -20.1 ± 10.91 | 7.1 ± 24.38 | — |
| Day 510 | — | — | -11.8 ± 25.33 |
| Day 720 (study completion) | — | — | -13.0 ± 23.65 |
Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -73.8 ± 68.01 | 28.8 ± 94.01 | — |
| Day 330 | -74.4 ± 57.63 | 4.3 ± 82.16 | — |
| Day 360 | -60.0 ± 44.74 | 6.0 ± 56.11 | — |
| Day 510 | — | — | -51.4 ± 81.53 |
| Day 720 (study completion) | — | — | -45.8 ± 89.10 |
Percentage change in total cholesterol from baseline to each assessment time up to Day 720.
| Percent change in total cholesterol | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -19.0 ± 12.49 | 16.0 ± 37.96 | — |
| Day 330 | -19.1 ± 10.30 | 8.7 ± 30.54 | — |
| Day 360 | -16.1 ± 9.53 | 6.8 ± 21.06 | — |
| Day 510 | — | — | -9.3 ± 20.73 |
| Day 720 (study completion) | — | — | -9.6 ± 20.86 |
Absolute change in total cholesterol from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -69.7 ± 67.42 | 29.5 ± 99.30 | — |
| Day 330 | -71.4 ± 56.65 | 8.8 ± 84.68 | — |
| Day 360 | -57.3 ± 43.82 | 10.0 ± 59.14 | — |
| Day 510 | — | — | -46.5 ± 80.87 |
| Day 720 (study completion) | — | — | -40.4 ± 88.44 |
Percentage change in triglycerides from baseline to each assessment time up to Day 720.
| Percent change in triglycerides | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | 0.3 ± 31.92 | -15.7 ± 5.97 | — |
| Day 330 | -9.6 ± 30.66 | -5.8 ± 31.90 | — |
| Day 360 | 11.4 ± 24.72 | 14.1 ± 54.93 | — |
| Day 510 | — | — | 4.7 ± 37.21 |
| Day 720 (study completion) | — | — | 2.9 ± 26.02 |
Absolute change in triglycerides from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -3.4 ± 23.80 | -15.0 ± 7.53 | — |
| Day 330 | -9.4 ± 21.98 | -2.3 ± 25.01 | — |
| Day 360 | 8.7 ± 24.15 | 28.0 ± 72.23 | — |
| Day 510 | — | — | 3.3 ± 34.32 |
| Day 720 (study completion) | — | — | 3.9 ± 27.40 |
Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
| Percent change in HDL-C | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | 10.0 ± 13.22 | -0.1 ± 20.06 | — |
| Day 330 | 7.5 ± 12.93 | 10.9 ± 12.48 | — |
| Day 360 | 6.7 ± 20.60 | 9.2 ± 21.20 | — |
| Day 510 | — | — | 12.3 ± 17.63 |
| Day 720 (study completion) | — | — | 13.9 ± 18.81 |
Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | 4.1 ± 5.18 | 0.8 ± 7.50 | — |
| Day 330 | 3.0 ± 5.05 | 4.5 ± 5.07 | — |
| Day 360 | 2.7 ± 7.75 | 4.0 ± 8.76 | — |
| Day 510 | — | — | 4.9 ± 7.94 |
| Day 720 (study completion) | — | — | 5.4 ± 7.81 |
Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
| Percent change in VLDL-C | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -7.0 ± 70.31 | 74.5 ± 108.97 | — |
| Day 330 | -29.0 ± 49.96 | 2.0 ± 113.44 | — |
| Day 360 | -17.0 ± 60.36 | 34.6 ± 56.37 | — |
| Day 510 | — | — | 9.5 ± 98.44 |
| Day 720 (study completion) | — | — | -1.4 ± 69.03 |
Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -7.7 ± 11.39 | 8.5 ± 20.37 | — |
| Day 330 | -11.6 ± 11.71 | -7.5 ± 18.21 | — |
| Day 360 | -9.2 ± 17.89 | 10.3 ± 21.00 | — |
| Day 510 | — | — | -4.6 ± 18.41 |
| Day 720 (study completion) | — | — | -6.0 ± 18.81 |
Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
| Percent change in Apo A1 | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -0.9 ± 10.72 | -1.3 ± 2.27 | — |
| Day 330 | -2.1 ± 10.87 | 9.0 ± 7.02 | — |
| Day 360 | 3.1 ± 16.49 | 13.7 ± 12.99 | — |
| Day 510 | — | — | 12.8 ± 12.08 |
| Day 720 (study completion) | — | — | 6.5 ± 10.10 |
Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 150 | -1.2 ± 14.10 | -1.3 ± 2.36 | — |
| Day 330 | -2.7 ± 13.47 | 10.3 ± 7.41 | — |
| Day 360 | 4.2 ± 18.82 | 16.0 ± 14.79 | — |
| Day 510 | — | — | 14.9 ± 13.25 |
| Day 720 (study completion) | — | — | 7.4 ± 12.40 |
Percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.
| Percent change in PCSK9 | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 90 | -56.8 ± 13.73 | -17.3 ± 14.77 | — |
| Day 150 | -60.4 ± 12.62 | -1.7 ± 11.11 | — |
| Day 330 | -65.3 ± 12.51 | -5.1 ± 19.60 | — |
| Day 360 | -59.7 ± 9.05 | -2.8 ± 22.65 | — |
| Day 510 | — | — | -68.1 ± 10.57 |
| Day 720 (study completion) | — | — | -64.1 ± 12.12 |
Absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.
| ng/mL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Day 90 | -278.7 ± 113.31 | -98.5 ± 87.46 | — |
| Day 150 | -296.3 ± 118.18 | -6.1 ± 64.82 | — |
| Day 330 | -323.1 ± 129.32 | -35.3 ± 100.97 | — |
| Day 360 | -292.6 ± 100.44 | -14.0 ± 127.42 | — |
| Day 510 | — | — | -347.3 ± 106.3 |
| Day 720 (study completion) | — | — | -327.7 ± 110.4 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 90 days post treatment or 30 days after last study visit, whichever was longer, up to a maximum duration of approximately 2 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - Inclisiran | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Part 1 - Placebo | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part 2 - Inclisiran (Total) | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Event | Part 1 - Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| COVID-19Infections and infestations | 4/9 | 1/4 | 1/13 |
| GastroenteritisInfections and infestations | 1/9 | 1/4 | 0/13 |
| GingivitisInfections and infestations | 0/9 | 1/4 | 0/13 |
| Oral herpesInfections and infestations | 0/9 | 1/4 | 0/13 |
| Vaginal dischargeReproductive system and breast disorders | 0/9 | 1/4 | 0/13 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/9 | 1/4 | 0/13 |
| UrticariaSkin and subcutaneous tissue disorders | 0/9 | 1/4 | 0/13 |
| Abdominal pain upperGastrointestinal disorders | 2/9 | 0/4 | 1/13 |
| Injection site reactionGeneral disorders | 2/9 | 0/4 | 0/13 |
| PyrexiaGeneral disorders | 2/9 | 0/4 | 0/13 |
Baseline Characteristics are based on all randomized participants
| Age, Categorical(Participants) | Part 1- Inclisiran | Part 1 - Placebo | Total |
|---|---|---|---|
| <=18 years | 9 | 4 | 13 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Part 1- Inclisiran | Part 1 - Placebo | Total |
|---|---|---|---|
| Mean | 14.6 ± 1.54 | 15.1 ± 2.66 | 14.8 ± 1.85 |
| Sex: Female, Male(Participants) | Part 1- Inclisiran | Part 1 - Placebo | Total |
|---|---|---|---|
| Female | 7 | 2 | 9 |
| Male | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | Part 1- Inclisiran | Part 1 - Placebo | Total |
|---|---|---|---|
| Asian | 1 | 1 | 2 |
| White | 8 | 3 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2021 to primary completion in Oct 2023, 32 months.
Results were first posted in May 2025, 1 year 7 months after primary completion. A results delay was requested in Jun 2024.
Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 32 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran
Homozygous Familial Hypercholesterolemia →